The use of the “gene ao probe” platform which embraces molecular biology, cell biology, structural biology and medicinal chemistry to identify new therapeutic targets and develop potent inhibitors for these targets. Highly specialized researchers, belonging to SGC-UNICAMP, guarantee the efficiency in the execution of the platform.

Potential therapeutic targets are chosen by researchers from the SGC consortium in partnership with researchers from Brazilian companies focusing on oncological, inflammatory, neurodegenerative and infectious diseases.